Join ASTP and the National Cancer Institute for a listening session on the USCDI+ Cancer Clinical Trials Matching (CTM) and immune-related Adverse Events (irAE) draft datasets.
USCDI+ Cancer Clinical Trials Matching (CTM)
The USCDI+ Cancer CTM dataset aims to establish a standardized set of data elements reported in a consistent format. By focusing on key screening data, this dataset will support generating a list of potential trials for which a patient may be eligible. This will streamline the matching process, making trial matching more equitable and accessible for all patients, and enabling patients, healthcare providers, and researchers to engage more effectively in cancer treatment decisions and care planning.
USCDI+ Cancer immune-related Adverse Events (irAE)
The immune-related Adverse Events (irAEs) use case within the USCDI+ Cancer initiative aims to significantly enhance the accuracy and reliability of detecting signals for immune-related adverse events using real-world data. This effort focuses on defining and refining standardized structured data elements that are crucial for identifying signals associated with common immune-related checkpoints for participants in clinical trials.